A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide
(2019) In Scandinavian Journal of Urology 53(5). p.312-318- Abstract
Objective: This retrospective, single-centre, non-interventional, registry-based study evaluated patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in daily clinical practice at Skåne University Hospital, Malmö, Sweden. Materials and methods: Registry data were reviewed for patients treated with enzalutamide pre- or post-chemotherapy initiated between December 2013 and June 2017. The primary endpoint was overall survival (OS) in post-chemotherapy patients. Secondary endpoints were enzalutamide treatment duration in the pre- and post-chemotherapy setting. This study was approved by the Lund regional Ethics Review Board (Dnr:2017/716) and is registered with ClinicalTrials.gov (NCT03328364).... (More)
Objective: This retrospective, single-centre, non-interventional, registry-based study evaluated patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in daily clinical practice at Skåne University Hospital, Malmö, Sweden. Materials and methods: Registry data were reviewed for patients treated with enzalutamide pre- or post-chemotherapy initiated between December 2013 and June 2017. The primary endpoint was overall survival (OS) in post-chemotherapy patients. Secondary endpoints were enzalutamide treatment duration in the pre- and post-chemotherapy setting. This study was approved by the Lund regional Ethics Review Board (Dnr:2017/716) and is registered with ClinicalTrials.gov (NCT03328364). Results: A total of 102 pre-chemotherapy and 98 post-chemotherapy patients were included. Median age was higher in the pre- than in the post-chemotherapy group (77 vs 72 years, respectively). Median OS in post-chemotherapy patients from initiation of enzalutamide until death from any cause was 14.3 months [95% confidence interval (CI) = 11.00–18.20]. Median treatment duration was 13.8 months (95% CI = 11.4–20.2) and 7.6 months (95% CI = 6.3–10.2) for pre- and post-chemotherapy patients, respectively. Conclusion: Enzalutamide can be used to effectively treat mCRPC patients in daily clinical settings, despite the patients being older and less healthy than those enrolled in the previous randomised, clinical registration studies.
(Less)
- author
- Alghazali, Mohammed LU ; Löfgren, Annica LU ; Jørgensen, Leif ; Svensson, Maja ; Fagerlund, Karin and Bjartell, Anders LU
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Enzalutamide, metastatic castration-resistant prostate cancer, registries
- in
- Scandinavian Journal of Urology
- volume
- 53
- issue
- 5
- pages
- 312 - 318
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:85071972443
- pmid:31815592
- ISSN
- 2168-1805
- DOI
- 10.1080/21681805.2019.1657494
- language
- English
- LU publication?
- no
- id
- 108068ae-6368-43d5-a37c-23b39b1ba172
- date added to LUP
- 2019-09-18 15:10:16
- date last changed
- 2024-08-21 08:19:14
@article{108068ae-6368-43d5-a37c-23b39b1ba172, abstract = {{<p>Objective: This retrospective, single-centre, non-interventional, registry-based study evaluated patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in daily clinical practice at Skåne University Hospital, Malmö, Sweden. Materials and methods: Registry data were reviewed for patients treated with enzalutamide pre- or post-chemotherapy initiated between December 2013 and June 2017. The primary endpoint was overall survival (OS) in post-chemotherapy patients. Secondary endpoints were enzalutamide treatment duration in the pre- and post-chemotherapy setting. This study was approved by the Lund regional Ethics Review Board (Dnr:2017/716) and is registered with ClinicalTrials.gov (NCT03328364). Results: A total of 102 pre-chemotherapy and 98 post-chemotherapy patients were included. Median age was higher in the pre- than in the post-chemotherapy group (77 vs 72 years, respectively). Median OS in post-chemotherapy patients from initiation of enzalutamide until death from any cause was 14.3 months [95% confidence interval (CI) = 11.00–18.20]. Median treatment duration was 13.8 months (95% CI = 11.4–20.2) and 7.6 months (95% CI = 6.3–10.2) for pre- and post-chemotherapy patients, respectively. Conclusion: Enzalutamide can be used to effectively treat mCRPC patients in daily clinical settings, despite the patients being older and less healthy than those enrolled in the previous randomised, clinical registration studies.</p>}}, author = {{Alghazali, Mohammed and Löfgren, Annica and Jørgensen, Leif and Svensson, Maja and Fagerlund, Karin and Bjartell, Anders}}, issn = {{2168-1805}}, keywords = {{Enzalutamide; metastatic castration-resistant prostate cancer; registries}}, language = {{eng}}, number = {{5}}, pages = {{312--318}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Journal of Urology}}, title = {{A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide}}, url = {{http://dx.doi.org/10.1080/21681805.2019.1657494}}, doi = {{10.1080/21681805.2019.1657494}}, volume = {{53}}, year = {{2019}}, }